Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAXUS Liberté- TAXUS Express · 4 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | OTHER | Control data derived from ATLAS Workhorse Trial |
| Arm 3 | OTHER | Historical Comparator: control data derived from a TAXUS V de novo lesion size-matched cohort randomized to receive a 2.25 mm or 2.5 mm BMS |
| Name | Type | Description |
|---|---|---|
| TAXUS Liberté™-SR | DEVICE | Paclitaxel-Eluting Coronary Stent System |
| TAXUS Liberté-SR | DEVICE | Paclitaxel-Eluting Coronary 38 mm Stent |
| TAXUS™ Express | DEVICE | Paclitaxel-Eluting Coronary Stent System |
| TAXUS™ Express2 | DEVICE | Paclitaxel-Eluting Coronary Stent System |
| Express2 | DEVICE | Coronary Stent System |
General Inclusion Criteria: 1. Patient is ≥18 years old. 2. Eligible for percutaneous coronary intervention (PCI) 3. Documented stable angina pectoris or unstable angina pectoris with documented ischemia, or documented silent ischemia 4. Left ventricular ejection fraction (LVEF) of ≥25% 5. Acceptab...
TAXUS Liberté is a drug-eluting stent used for the treatment of coronary artery disease. It is designed to open narrowed or blocked coronary arteries and deliver a drug to help prevent restenosis. The stent is currently in Phase 3 clinical development and is not yet approved by the FDA.
TAXUS Liberté is developed by Boston Scientific Corporation, a medical device company traded on the New York Stock Exchange under the ticker symbol BSX. The company is conducting Phase 3 clinical trials to evaluate the safety and effectiveness of the stent in patients with coronary artery disease.
TAXUS Liberté is in Phase 3 clinical development. It is an investigational drug-eluting stent being studied for the treatment of coronary artery disease. The Phase 3 trials have been completed, but the product has not yet received FDA approval and remains under clinical investigation.
TAXUS Liberté has been studied in four completed Phase 3 clinical trials: NCT00371423, NCT00371475, NCT00371709, and NCT00371748. These trials evaluated the stent in patients with de novo coronary artery lesions, including long lesions and small vessels, across multiple countries including the United States, New Zealand, Singapore, and Taiwan.
TAXUS Liberté is a distinct stent system from TAXUS Express, though both are drug-eluting stents developed by Boston Scientific for coronary artery disease. The Liberté platform features a different stent design compared to the Express platform, and they have been studied in separate clinical trials.